Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abingworth Attracts $375M For Its New Bioventures Fund

This article was originally published in Start Up

Executive Summary

The committed capital is nearly half what the 40-year-old firm raised from its previous vehicle and its sidecar in 2007–2008, but it's a huge sum compared with what most life science VCs can drum up these days.

You may also be interested in...

In More RNAi Demand, Preclinical Dicerna IPO Piques Investor Interest

The biotech took advantage of rising investor interest in RNAi to pull off a heavily oversubscribed IPO.

Wellcome Trust’s Syncona Bets On Gene Therapy in Eye Disease

The profit-oriented evergreen fund of Britain’s charitable foundation The Wellcome Trust, Syncona, has invested £12 million in an academic spin-out to develop and commercialize therapies for treating degenerative eye diseases.

Algeta, Aspiring For Solo Success, Draws Bayer Bid After Xofigo Launch

The Norwegian biotech is keen to show it is not a one-trick pony, but its future might lie in the embrace of its big pharma partner Bayer.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts